Suppr超能文献

通过微透析研究扎西他滨(2',3'-双脱氧胞苷)和BEA005(2',3'-双脱氧-3'-羟甲基胞苷)在大鼠体内的药代动力学及血脑屏障分布情况。

Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis.

作者信息

Borg N, Ståhle L

机构信息

Department of Clinical Pharmacology, Huddinge Hospital, SE-14186, Huddinge, Sweden.

出版信息

Antimicrob Agents Chemother. 1998 Sep;42(9):2174-7. doi: 10.1128/AAC.42.9.2174.

Abstract

Microdialysis was applied to sample the unbound drug concentration in the extracellular fluid in brain and muscle of rats given zalcitabine (2',3'-dideoxycytidine; n = 4) or BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine; n = 4) (50 mg/kg of body weight given subcutaneously). Zalcitabine and BEA005 were analyzed by high-pressure liquid chromatography with UV detection. The maximum concentration of zalcitabine in the dialysate (Cmax) was 31.4 +/- 5. 1 microM (mean +/- standard error of the mean) for the brain and 238. 3 +/- 48.1 microM for muscle. The time to Cmax was found to be from 30 to 45 min for the brain and from 15 to 30 min for muscle. Zalcitabine was eliminated from the brain and muscle with half-lives 1.28 +/- 0.64 and 0.85 +/- 0.13 h, respectively. The ratio of the area under the concentration-time curve (AUC) (from 0 to 180 min) for the brain and the AUC for muscle (AUC ratio) was 0.191 +/- 0.037. The concentrations of BEA005 attained in the brain and muscle were lower than those of zalcitabine, with Cmaxs of 5.7 +/- 1.4 microM in the brain and 61.3 +/- 12.0 microM in the muscle. The peak concentration in the brain was attained 50 to 70 min after injection, and that in muscle was achieved 30 to 50 min after injection. The half-lives of BEA005 in the brain and muscle were 5.51 +/- 1.45 and 0.64 +/- 0.06 h, respectively. The AUC ratio (from 0 to 180 min) between brain and muscle was 0.162 +/- 0.026. The log octanol/water partition coefficients were found to be -1.19 +/- 0.04 and -1.47 +/- 0.01 for zalcitabine and BEA005, respectively. The degrees of plasma protein binding of zalcitabine (11% +/- 4%) and BEA005 (18% +/- 2%) were measured by microdialysis in vitro. The differences between zalcitabine and BEA005 with respect to the AUC ratio (P = 0.481), half-life in muscle (P = 0.279), and level of protein binding (P = 0.174) were not statistically significant. The differences were statistically significant in the case of the half-life in the brain (P = 0.032), clearance (P = 0.046), volume of distribution (P = 0.027) in muscle, and octanol/water partition coefficient (P = 0.019).

摘要

采用微透析技术对皮下注射扎西他滨(2',3'-双脱氧胞苷;n = 4)或BEA005(2',3'-双脱氧-3'-羟甲基胞苷;n = 4)(50mg/kg体重)的大鼠脑和肌肉细胞外液中的游离药物浓度进行采样。扎西他滨和BEA005采用高压液相色谱-紫外检测法进行分析。扎西他滨在透析液中的最大浓度(Cmax)在脑中为31.4±5.1μM(平均值±平均标准误差),在肌肉中为238.3±48.1μM。达到Cmax的时间在脑中为30至45分钟,在肌肉中为15至30分钟。扎西他滨在脑和肌肉中的消除半衰期分别为1.28±0.64小时和0.85±0.13小时。脑浓度-时间曲线下面积(AUC)(0至180分钟)与肌肉AUC的比值(AUC比值)为0.191±0.037。BEA005在脑和肌肉中达到的浓度低于扎西他滨,脑中Cmax为5.7±1.4μM,肌肉中为61.3±12.0μM。脑内峰值浓度在注射后50至70分钟达到,肌肉中在注射后30至50分钟达到。BEA005在脑和肌肉中的半衰期分别为5.51±1.45小时和0.64±0.06小时。脑和肌肉之间的AUC比值(0至180分钟)为0.162±0.026。扎西他滨和BEA005的正辛醇/水分配系数分别为-1.19±0.04和-1.47±0.01。采用体外微透析法测定扎西他滨(11%±4%)和BEA005(18%±2%)的血浆蛋白结合率。扎西他滨和BEA005在AUC比值(P = 0.481)、肌肉半衰期(P = 0.279)和蛋白结合水平(P = 0.174)方面的差异无统计学意义。在脑半衰期(P = 0.032)、肌肉清除率(P = 0.046)、分布容积(P = 0.027)和正辛醇/水分配系数(P = 0.019)方面差异有统计学意义。

相似文献

5
The effects of renal impairment on the pharmacokinetics of zalcitabine.
J Clin Pharmacol. 1998 Jan;38(1):28-33. doi: 10.1002/j.1552-4604.1998.tb04373.x.
6
Altered pharmacokinetics of zalcitabine by concurrent use of NSAIDs in rats.
Acta Pharmacol Sin. 2006 Jan;27(1):119-22. doi: 10.1111/j.1745-7254.2006.00249.x.

引用本文的文献

4
A recursive-partitioning model for blood-brain barrier permeation.一种用于血脑屏障渗透的递归划分模型。
J Comput Aided Mol Des. 2005 Jul;19(7):465-81. doi: 10.1007/s10822-005-9001-7. Epub 2005 Dec 6.

本文引用的文献

3
Microdialysis in pharmacokinetics.
Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):89-96. doi: 10.1007/BF03220011.
4
Zero and first moment area estimation from microdialysis data.
Eur J Clin Pharmacol. 1993;45(5):477-81. doi: 10.1007/BF00315521.
5
Zalcitabine. Clinical pharmacokinetics and efficacy.扎西他滨。临床药代动力学与疗效。
Clin Pharmacokinet. 1995 May;28(5):351-60. doi: 10.2165/00003088-199528050-00002.
9
Microdialysis sampling for determination of plasma protein binding of drugs.
Pharm Res. 1990 Oct;7(10):1077-81. doi: 10.1023/a:1015955503708.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验